Proton pump inhibitors (PPIs) are very effective and suitable for certain indications and treatment periods, but there is an increasing trend towards “off-label” prescriptions. To ensure that temporary administration for a specific indication does not become an unreflected permanent medication, North American experts have summarized ten best practice recommendations to help decide whether discontinuation (“deprescribing”) of PPIs could be an option to consider.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
- GASTROENTEROLOGIE PRAXIS
Related Topics
You May Also Like
- cSCC: Personalizing Treatment Strategies and Follow-up Care Plans
Comprehensive risk stratification is no simple matter: what’s new?
- Baxdrostat – a new class of drugs for treating difficult-to-control hypertension
First Aldosterone Synthase Inhibitor Is Here
- Geriatric Small-Cell Lung Cancer
Therapeutic Challenges
- Chronic Pruritus in Renal, Hepatic, and Biliary Tract Diseases
Pooled Expertise for Targeted Evaluation and Treatment
- Advanced Thyroid Cancer
Molecular Mechanisms and New Therapeutic Approaches
- Epidermolysis bullosa
Promoting Wound Healing with Gene Therapies and Birch Bark Extract
- From Risk Identification to Anti-Inflammatory Intervention
Inflammation as a Treatment Goal in Its Own Right
- Psoriasis Research: What's in the Pipeline?